Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of CancerElise A. Olsen, Eric C. Vonderheid, Sean Whittaker et al.|Journal of Clinical Oncology|2011Cited by 657
Mental Health Service Use in the Community and Schools: Results from the Four-Community MECA StudyPhilip J. Leaf, Darrel A. Regier, Margarita Alegrı́a et al.|Journal of the American Academy of Child & Adolescent Psychiatry|1996Cited by 609
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH. Miles Prince, M. D’Incan, Judith Trotman et al.|The Lancet|2017Cited by 580
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic ModelJulia Scarisbrick, Henry K. Wong, H. Miles Prince et al.|Journal of Clinical Oncology|2015Cited by 419
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTCElise A. Olsen, Julia Scarisbrick, Sean Whittaker et al.|Blood|2021Cited by 170